Like many ACE inhibitors, this [[prodrug]] is converted to the active metabolite [[spiraprilat]] following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes, which may allow for greater use in patients with renal impairment.<ref>{{cite journal |vauthors=Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G | title = Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension. | journal = Scand J Urol Nephrol | volume = 33 | issue = 1 | pages = 57&ndash;62 | year = 1999 | pmid = 10100366 | doi = 10.1080/003655999750016294}}</ref>
